Two weeks ago, Takeda Pharmaceuticals raised the list price of its Entyvio treatment for ulcerative colitis and Crohn’s disease by 4%, to nearly $7,000 for a vial. This followed an earlier 4% price hike last January, which means the company boosted the list price for its medicine by 8% this year.
Whether such an increase in one calendar year is beyond the pale is debatable. After President Trump bullied drug makers over pricing in 2018, many companies tried to lower their profiles by curtailing or restricting annual price hikes to less than 10%. This past July, for instance, drug prices rose an average of 3.1% for 67 brand-name medicines, according to GoodRx.
About the Author Reprints
